Updates in the Treatment of AmpC-Producing Enterobacterales
Classical Presentation- Objectives:
- This presentation will cover the following:
- Understanding the mechanism of AmpC-mediated resistance
- Discussing the previous management of AmpC-producing Enterobacterales
- Presenting the updates in the management of AmpC-producing Enterobacterales (including IDSA updated guidelines)
- The novel antibiotic and combination therapy options
Current Treatment Approach for CRAB
Classical PresentationObjectives:
This presentation will cover the following:
Understanding the mechanism of resistance and the threat of CRAB
Identifying genotypes that underlie resistant phenotypes
Discussing the traditional management of Acinetobacter spp.
The clinical challenges of CRAB treatment
The characteristics and roles of new agents
Proposed treatment strategies for CRAB
Therapeutic Drug Monitoring (TDM): An Underestimated Powerful Tool
Classical PresentationObjectives:
Clear the ambiguity around “Therapeutic Drug Monitoring”! This presentation will cover the following key points:
Understanding TDM and the importance of dose optimization
Understanding different related terminology (e.g., trough, peak, area under the curve), their indications, and relevance
Understanding the basis of dosing, intervals, and special administration methods (e.g., extended infusion time)
The crucial role and utility of TDM in the treatment of infectious diseases
Practical and novel approaches to therapeutic drug monitoring and antibiotic dosing
Staying Ahead of Infectious Diseases: Pipelines Corner
(Co-organized with the Saudi Society of Clinical Pharmacy) Presentation and Open DiscussionObjectives:
This session will introduce you to the recently approved and soon-to-be-approved antimicrobials. It will keep you one step away from using the novel antibiotics, antifungals, and antivirals. It additionally covers issues related to their use, spectra, indications, and limitations. Look no further; join the antimicrobial pipeline session!
SPIDS Plenary: Ventilator-Associated Pneumonia: Connecting the Dots
Open Discussion (Forum)Objectives:
A general and thorough review of ventilator-associated pneumonia that touches on:
The current definition of VAP in pediatrics
Diagnosis-related issues such as the challenges of establishing an accurate VAP diagnosis, sampling (the role of mini-BAL), the performance/positive predictive values of different diagnostic parameters (e.g., respiratory symptoms, ventilatory parameters, radiological findings, etc.)
Therapeutic-related issues (e.g., the role of combination therapy, empiric use of anti-staphylococcal and anti-pseudomonal agents, the impact of the recent CLSI breakpoint changes on the empiric and definitive use of aminoglycosides, the duration of therapy, the role of inhaled antimicrobials)
The impact of MRSA screening on treatment
Empiric Antibiotics in the NICU: Is It Still Aminoglycosides?
Classical PresentationObjectives:
Are we moving away from our long-standing practice for neonatal sepsis, or are we still holding tight to ampicillin and gentamicin? Define your future practice after this eye-opening presentation, which includes:
A brief overview of the current practice (ampicillin/aminoglycoside) for neonatal sepsis, the origin behind this recommendation, rationales, and the validity of this recommendation in the present time
The indications/scenarios where deviation from this practice is recommended and the appropriate alternatives
The impact of the new CLSI and EUCAST aminoglycoside breakpoints on these recommendations
Challenges and limitations
Understanding Culture-Negative Sepsis
Classical PresentationObjectives:
Do you believe in “culture-negative sepsis”? This presentation will answer this question and many others:
What is culture-negative sepsis in newborns?
Are we diagnosing culture-negative sepsis? What are the criteria for culture-negative sepsis?
The role of common laboratory biomarkers and diagnostic imaging
When to treat culture-negative sepsis?
How culture-negative sepsis compares to culture-positive sepsis (morbidity and mortality)
Management considerations (e.g., the role of de-escalation, duration, etc.)
Perinatal HIV: The Current Approach for Prevention
Classical PresentationObjectives:
This presentation will cover the following issues:
Epidemiology of perinatal HIV infection
Risk factors that lead to increased perinatal HIV transmission (regionally)
Preventive measures needed to prevent perinatal HIV transmission to children
Highlights on the recent changes in the recommendations for the prevention of perinatal HIV transmission, including the local recommendations
Imaging Approaches for Patients with Fever of Unknown Origin
Classical PresentationPending